An Jung Nam, Kim Sung Gyun, Song Young Rim
Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Hallym University Kidney Research Institute, Anyang, Republic of Korea.
Kidney Res Clin Pract. 2021 Dec;40(4):566-577. doi: 10.23876/j.krcp.21.043. Epub 2021 Nov 1.
Acute kidney injury (AKI) is a common condition in critically ill patients, and may contribute to significant medical, social, and economic consequences, including death. Although there have been advances in medical technology, including continuous renal replacement therapy (CRRT), the mortality rate of AKI is high, and there is no fundamental treatment that can reverse disease progression. The decision to implement CRRT is often subjective and based primarily on the clinician's judgment without consistent and concrete guidelines or protocols regarding when to initiate and discontinue CRRT and how to manage complications. Recently, several randomized controlled trials addressing the initiation of renal replacement therapy in critically ill patients with AKI have been completed, but clinical application of the findings is limited by the heterogeneity of the objectives and research designs. In this review, the advantages and disadvantages of CRRT initiation, clinical guideline recommendations, and the results of currently published clinical trials and meta-analyses are summarized to guide patient care and identify future research priorities.
急性肾损伤(AKI)是危重症患者的常见病症,可能导致重大的医学、社会和经济后果,包括死亡。尽管包括持续肾脏替代治疗(CRRT)在内的医学技术已有进展,但AKI的死亡率仍然很高,且尚无能够逆转疾病进展的根本治疗方法。实施CRRT的决定往往具有主观性,主要基于临床医生的判断,缺乏关于何时开始和停止CRRT以及如何处理并发症的一致且具体的指南或方案。最近,几项针对AKI危重症患者启动肾脏替代治疗的随机对照试验已经完成,但研究结果的临床应用受到目标和研究设计异质性的限制。在本综述中,总结了启动CRRT的优缺点、临床指南建议以及当前已发表的临床试验和荟萃分析的结果,以指导患者护理并确定未来的研究重点。